Get A Quote
Inquiry

Polyethylene Glycol in PROTAC Linkers

Polyethylene glycol (PEG) is a polyether compound with the molecular formula (C₂H₄O)ₙ. It is a versatile polymer that is water-soluble and biocompatible. PEG is widely used in the pharmaceutical, biomedical, and biotechnology industries due to its ability to modify the physiochemical properties of molecules. In the development of proteolysis-targeting chimeras (PROTACs), PEG-based linkers are frequently used due to their hydrophilicity, flexibility, and ability to enhance cell permeability. These properties enable the efficient recruitment of E3 ligase to the target protein, facilitating ubiquitination and subsequent proteasomal degradation. Thus, PEG contributes significantly to the efficacy and pharmacokinetic properties of PROTACs in targeted protein degradation therapy.

Proteolysis Targeting Chimera

Proteolysis Targeting Chimeras (PROTACs) are novel, innovative molecules designed for targeted protein degradation within cells. They represent a revolutionary approach in drug discovery and development by enabling the selective destruction of specific proteins, rather than merely inhibiting their function. PROTACs consist of three key components: a ligand that binds to the target protein, a ligand that recruits an E3 ubiquitin ligase, and a linker that connects these two ligands.

Structure of PROTACFig. 1. The structure of PROTAC (Explor Target Antitumor Ther. 2020, 1(5): 273-312).

The core mechanism of a PROTAC involves hijacking the ubiquitin-proteasome system (UPS), which is a cellular machinery responsible for degrading unwanted or misfolded proteins. The ubiquitin-proteasome system works through the action of three enzymes: E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase). The role of the E3 ligase is crucial as it confers specificity by recognizing the target protein, thus determining which proteins get ubiquitinated and subsequently degraded by the proteasome. Here's a detailed description of how PROTACs operate:

  1. Binding to the Target Protein: One end of the PROTAC molecule has a ligand that binds specifically to the target protein, which the researchers aim to degrade.
  2. Recruitment of E3 Ubiquitin Ligase: The opposite end of the PROTAC molecule binds to an E3 ubiquitin ligase, an enzyme that transfers ubiquitin molecules (small proteins used as cellular signals) to the bound target protein.
  3. Ubiquitination: Upon binding both the target protein and the E3 ligase, PROTAC brings these two proteins into close proximity, allowing the E3 ligase to transfer ubiquitin molecules to the target protein.
  4. Degradation via the Proteasome: The ubiquitinated target protein is recognized by the proteasome, a complex that degrades and recycles proteins. The target protein is broken down into small peptides, effectively reducing its cellular level.

This mechanism allows PROTACs to degrade proteins rather than just inhibit them, as traditional small-molecule inhibitors do. One of the significant advantages of PROTACs is their catalytic nature; they can engage multiple target protein molecules, perpetuating their degradation without themselves being consumed in the process.

What are PROTAC Linkers?

The linker in a PROTAC molecule is a chemical spacer that bridges the target-binding ligand and the E3 ligase-binding ligand. This linker must possess specific characteristics to ensure the proper spatial orientation and positioning of the ligands, allowing the effective recruitment of the E3 ligase to the target protein. Successful recruitment facilitates the polyubiquitination and subsequent degradation of the target protein by the 26S proteasome, a proteolytic complex within the cell. The choice of linker can significantly impact the potency, selectivity, and cellular permeability of the PROTAC molecule. Currently, the types of PROTAC linkers include:

PROTAC Linkers from BOC Sciences

CatalogNameCASPrice
BPG-1773Amino-PEG3-propionic acid784105-33-5Inquiry
BPG-1720Azido-PEG3-alcohol86520-52-7Inquiry
BPG-1705Propargyl-PEG2-amine944561-44-8Inquiry
BPG-1978Azido-PEG5-propionic acid1425973-16-5Inquiry
BPG-2280Azido-PEG9-acid1670249-37-2Inquiry
BPG-2009Amino-PEG6-propionic acid905954-28-1Inquiry
BPG-1922Tos-PEG3-alcohol77544-68-4Inquiry
BPG-2006Azido-PEG7-alcohol1274892-60-2Inquiry

PROTAC Linker Design

The design of a PROTAC linker is a complex process that involves balancing length, flexibility, chemical properties, and spatial conformation. Precise optimization of the linker can significantly enhance the selectivity, cellular permeability, and pharmacological properties of the PROTAC, laying a solid foundation for the development of next-generation small-molecule degraders.

Linker Length and Flexibility

The length and flexibility of the linker are critical for facilitating the efficient formation of a ternary complex between the target protein and the E3 ligase. Generally, a longer linker provides greater spatial freedom, which can aid in stabilizing the interaction between the target protein and the E3 ligase. However, an overly long linker may reduce the efficiency of ternary complex formation. Flexibility refers to the rotational and conformational adaptability of the linker, which determines the overall conformation and fit of the PROTAC molecule. An ideal linker should be of sufficient length and maintain appropriate flexibility to promote effective protein-protein interactions.

Chemical Properties of the Linker

The chemical properties of the linker, such as polarity, hydrophilicity, and hydrophobicity, directly affect the cell permeability and solubility of the PROTAC molecule. Typically, a hydrophilic linker can improve the water solubility of the PROTAC but may limit its ability to penetrate cell membranes. Conversely, a more hydrophobic linker can enhance membrane permeability but may present solubility challenges. Therefore, the design process must carefully balance the polarity distribution of the linker to optimize both solubility and cellular uptake.

Functional Modifications

Functional modifications can be introduced into the linker to further optimize the pharmacokinetic and pharmacodynamic properties of the PROTAC. For instance, incorporating polyethylene glycol (PEG) chains can increase the molecule's water solubility and circulation time while reducing immunogenicity. Additionally, incorporating cleavable bonds that are susceptible to enzymatic or chemical degradation enables temporal and spatial control over the release of the PROTAC, enhancing tissue specificity and stability.

Stereoselectivity and Spatial Conformation

The stereoselectivity and spatial conformation of the linker are also critical for maintaining the stability of the ternary complex and the efficiency of target degradation. Designing the linker with specific stereochemistry, such as introducing chiral centers, can enhance the selectivity and activity of the PROTAC molecule. Optimizing the linker conformation helps reduce nonspecific protein-protein interactions and improves the efficiency of target protein degradation.

PEG Linkers for PROTAC Synthesis

As the most commonly used linker motif in PROTACs, PEG linkers are utilized in approximately 54% of reported PROTAC structures. Their widespread use is attributed to several key benefits they provide in enhancing the overall performance of these molecules.

** Recommended Products **

CatalogNameCASPrice
BPG-1709Amino-PEG3-alcohol6338-55-2Inquiry
BPG-1855Amino-PEG4-propionic acid663921-15-1Inquiry
BPG-2210Azido-PEG8-propionic acid1214319-92-2Inquiry
BPG-1869Propargyl-PEG5-amine1589522-46-2Inquiry
BPG-1900t-Boc-N-Amido-PEG3-Amine101187-40-0Inquiry
BPG-1904t-Boc-N-amido-PEG4-alcohol106984-09-2Inquiry
BPG-1752t-boc-N-amido-PEG2-alcohol139115-91-6Inquiry
BPG-1830t-boc-N-amido-PEG3-alcohol139115-92-7Inquiry
BPG-1849Azido-PEG4-amine951671-92-4Inquiry
BPG-1826Azido-PEG3-acid1056024-94-2Inquiry
BPG-1898Azido-PEG4-propionic acid1257063-35-6Inquiry
BPG-1719Azido-PEG2-amine166388-57-4Inquiry
BPG-1838mPEG5-alcohol23778-52-1Inquiry
BPG-2054Azido-PEG6-propionic acid361189-66-4Inquiry

Reference

  1. Troup, R.I. et al. Current strategies for the design of PROTAC linkers: a critical review. Explor Target Antitumor Ther. 2020, 1(5): 273-312.

Online Inquiry

Verification code

Copyright © 2026 BOC Sciences. All rights reserved.